Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice
Biocatalysis and Agricultural Biotechnology January 25, 2024 Timur Zanikov, Marta Gerasymchuk, Gregory Ian Robinson et al. 10 citations
Oral psilocybin and eugenol, given after inflammation was induced in a colitis mouse model, each reduced pro-inflammatory cytokines and mediators in the brain, including IL-1β, IL-6, and COX-2. The combined treatment produced the strongest reduction in IL-6 levels compared to the colitis group. However, across all markers, the combination did not show synergistic anti-inflammatory effects. These findings support the therapeutic potential of both compounds for psychiatric and neurodegenerative inflammatory disorders, though further research is needed to clarify mechanisms and clinical efficacy.